All Categories
Refine Search
GZD824
A novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
HA-15
Novel antitumor agent, triggering ER stress, exerting anti-melanoma effects and overcoming BRAF inhibitor resistance
HA130
Selective autotaxin inhibitor, inhibiting ATX-mediated cell migration in an A2058 melanoma cell assay